<p>Novo Nordisk A/S and Aspect Biosystems have announced a new phase in their partnership aimed at developing advanced cellular medicines for diabetes. Under this expanded collaboration, Aspect will lead the development, manufacturing, and commercialization of therapies using stem cell-derived islet cell and hypoimmune cell engineering technologies acquired from Novo Nordisk. Novo Nordisk will provide additional equity investment and research funding, and retains rights to potentially expand its involvement in later-stage development and commercialization. The agreement also involves integrating select Novo Nordisk research and manufacturing capabilities from the US and Denmark into Aspect’s Canadian platform, with the goal of accelerating the development of potentially curative therapies for diabetes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001160134-en) on January 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

Novo Nordisk and Aspect Biosystems Advance Partnership to Develop Curative Diabetes Therapies